2025
Comparison of Endovascular Interventions for the Treatment of Superficial Femoral Artery Disease: A Network Meta-analysis
Schwartz A, Shah Y, Huang H, Nathan A, Fanaroff A, Giri J, Parikh S, Lansky A, Shah T. Comparison of Endovascular Interventions for the Treatment of Superficial Femoral Artery Disease: A Network Meta-analysis. Journal Of The Society For Cardiovascular Angiography & Interventions 2025, 4: 102432. PMID: 40061407, PMCID: PMC11887560, DOI: 10.1016/j.jscai.2024.102432.Peer-Reviewed Original ResearchPercutaneous transluminal angioplastyCutting Balloon AngioplastyDrug-Coated BalloonBare metal stentsDrug-eluting stentsTreatment of SFA diseaseNetwork Meta-AnalysisSuperficial femoral arteryPrimary patencyTechnical successEndovascular techniquesEndovascular interventionSystematic literature search of PubMedLiterature search of PubMedEndovascular treatment modalitiesMeta-analysisSFA diseaseDe novo lesionsTarget lesion revascularizationSearch of PubMedCritical limb ischemiaSystematic literature searchTreatment modalitiesSuperficial femoral artery diseaseLesion revascularization
2013
Comparison of surgical bypass with angioplasty and stenting of superficial femoral artery disease
Malas M, Enwerem N, Qazi U, Brown B, Schneider E, Reifsnyder T, Freischlag J, Perler B. Comparison of surgical bypass with angioplasty and stenting of superficial femoral artery disease. Journal Of Vascular Surgery 2013, 59: 129-135. PMID: 23891488, DOI: 10.1016/j.jvs.2013.05.100.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonBaltimoreBlood Vessel Prosthesis ImplantationChi-Square DistributionFemaleFemoral ArteryHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisPeripheral Arterial DiseasePostoperative ComplicationsProportional Hazards ModelsRegistriesRisk FactorsStentsTime FactorsTreatment OutcomeVascular GraftingVascular PatencyVeinsConceptsPeripheral arterial diseaseFemoral-popliteal bypassPercutaneous transluminal angioplasty/stentingJohns Hopkins Bayview Medical CenterAngioplasty/stentingSuperficial femoral arteryReintervention rateTASC CSymptomatic patientsD lesionsMedical managementB lesionsFemoral arteryMedical CenterSuperficial femoral artery diseaseSymptomatic peripheral arterial diseaseFemoral artery diseaseTASC II ARate of reinterventionHigher reintervention rateBest treatment optionSimilar risk factorsProportional hazards modelTerms of patencyFisher's exact test
2005
Sirolimus-Eluting versus Bare Nitinol Stent for Obstructive Superficial Femoral Artery Disease: The SIROCCO II Trial
Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A, Anderson J, Wiesinger B, Tepe G, Lansky A, Mudde C, Tielemans H, Bérégi JP. Sirolimus-Eluting versus Bare Nitinol Stent for Obstructive Superficial Femoral Artery Disease: The SIROCCO II Trial. Journal Of Vascular And Interventional Radiology 2005, 16: 331-338. PMID: 15758128, DOI: 10.1097/01.rvi.0000151260.74519.ca.Peer-Reviewed Original ResearchConceptsSirolimus-eluting stent groupStent groupBare stent groupMean lumen diameterSignificant differencesLumen diameterSuperficial femoral artery diseaseSuperficial femoral artery obstructionChronic limb ischemiaFemoral artery diseaseFemoral artery obstructionAnkle-brachial indexBinary restenosis rateDouble-blind studySymptoms of claudicationBare nitinol stentsSirolimus-eluting stentsStandard interventional techniquesArtery obstructionPrimary endpointII trialAdverse eventsAngiographic outcomesArtery diseaseLimb ischemia
2004
Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results.
Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, Wiesinger B, Hak JB, Tielemans H, Ziemer G, Cristea E, Lansky A, Bérégi JP. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Journal Of Invasive Cardiology 2004, 16 Suppl A: 15a-19a. PMID: 23573600.Peer-Reviewed Original ResearchConceptsMean percent diameter stenosisSirolimus-eluting stent groupSerious adverse eventsFemoral artery occlusionPercent diameter stenosisStent groupArtery occlusionAdverse eventsArtery diseaseDiameter stenosisSuperficial femoral artery diseaseSuperficial femoral artery obstructionPoor long-term outcomesSuperficial femoral artery occlusionChronic limb ischemiaFemoral artery diseaseFemoral artery obstructionSuccessful guidewire passageUncoated-stent groupPrimary end pointFemoropopliteal artery diseaseSix-month resultsLong-term outcomesSirolimus-eluting stentsMean lumen diameter
2002
Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease
Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, Wiesinger B, Hak JB, Tielemans H, Ziemer G, Cristea E, Lansky A, Bérégi J. Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease. Circulation 2002, 106: 1505-1509. PMID: 12234956, DOI: 10.1161/01.cir.0000029746.10018.36.Peer-Reviewed Original ResearchConceptsMean percent diameter stenosisSirolimus-eluting stent groupSerious adverse eventsFemoral artery occlusionPercent diameter stenosisStent groupArtery occlusionAdverse eventsArtery diseaseDiameter stenosisSuperficial femoral artery diseaseSuperficial femoral artery obstructionPoor long-term outcomesSuperficial femoral artery occlusionChronic limb ischemiaFemoral artery diseaseFemoral artery obstructionSuccessful guidewire passageUncoated-stent groupPrimary end pointFemoropopliteal artery diseaseLong-term outcomesSirolimus-eluting stentsMean lumen diameterNitinol self-expanding stents
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply